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Abstract MITF (microphthalmia-associated transcription
factor) represents a melanocytic lineage-specific transcrip-
tion factor whose role is profoundly extended in malignant
melanoma. Over the last few years, the function of MITF
has been tightly connected to plasticity of melanoma cells.
MITF participates in executing diverse melanoma pheno-
types defined by distinct gene expression profiles.
Mutation-dependent alterations in MITF expression and
activity have been found in a relatively small subset of
melanomas. MITF activity is rather modulated by its
upstream activators and suppressors operating on tran-
scriptional, post-transcriptional and post-translational
levels. These regulatory mechanisms also include epige-
netic and microenvironmental signals. Several transcription
factors and signaling pathways involved in the regulation of
MITF expression and/or activity such as the Wnt/b-catenin
pathway are broadly utilized by various types of tumors,
whereas others, e.g., BRAFV600E/ERK1/2 are more specific
for melanoma. Furthermore, the MITF activity can be
affected by the availability of transcriptional co-partners
that are often redirected by MITF from their own canonical
signaling pathways. In this review, we discuss the com-
plexity of a multilevel regulation of MITF expression and
activity that underlies distinct context-related phenotypes of
melanoma and might explain diverse responses of mela-
noma patients to currently used therapeutics.
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Introduction
Melanocytes are pigment-producing cells whose differ-
entiation, proliferation and survival largely depend on
MITF (microphthalmia-associated transcription factor), a
melanocyte-specific transcription factor [for review 1, 2].
Melanoma is a melanocyte-derived tumor in which MITF
dependence is retained [for review 3]; thus, MITF rep-
resents a lineage-restricted regulator that operates in
normal cells, and its activity is also used by malignant
cells. Enforced expression of MITF in immortalized
melanocytes [4] or neural crest progenitor cells [5] when
introduced together with melanoma-specific BRAFV600E
suggests MITF’s role as a melanoma addiction oncogene.
MITF is recognized as a driver of melanoma progression
[for review 6], but its role in suppression of invasion and
metastasis has been also shown [7–10]. By activating the
expression of almost one hundred genes, MITF can reg-
ulate multiple biological processes in melanoma cells
such as differentiation, proliferation, migration, and
senescence [11–13; for review 14, 15]. MITF also exerts
pro-survival role by activating the expression of anti-
apoptotic genes including BCL2A1, BCL2 and BIRC7
(ML-IAP/livin) [for review 16, 17]. Recent studies
implicate MITF in energy metabolism and organelle
biogenesis [18; for review 19]. This variety of often
mutually exclusive cellular programs driven by MITF
stands for distinct phenotypes of melanoma cells [12, 20,
21; for review 22, 23]. MITF is also recognized as a
major regulator in a ‘‘phenotypic switching’’ concept
explaining a high plasticity of melanoma cells [20, 21,
24–27; for review 22, 28]. Therefore, better understanding
of the intracellular mechanisms underlying a contextual
regulation of MITF is of utmost importance. In this
review, we focus on melanoma-related mechanisms
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underlying the regulation of MITF expression and
activity.
Gene structure and transcriptional regulation of MITF
In human, MITF locus is mapped to chromosome 3 and
spans 229 kbp. MITF encodes a b-HLH-Zip (basic helix-
loop-helix leucine zipper) transcription factor that belongs
to the MYC superfamily. Together with TFEB, TFEC and
TFE3, MITF constitutes the MiT (microphthalmia) family
of transcription factors [29]. All of them share a common
b-HLH-Zip dimerization motif containing a positively
charged fragment involved in DNA binding, and a transac-
tivation domain (TAD) [29]. As a result of differential usage
of alternative promoters, a single MITF gene produces
several isoforms including MITF-A [30], MITF-B [31],
MITF-C [32], MITF-D [33], MITF-E [34], MITF-H [35],
MITF-J [36], MITF-Mc [37] and MITF-M [38, 39]. These
isoforms differ in their N-termini encoded by exon 1, and
show tissue-specific pattern of expression. The expression of
the shortest isoform MITF-M (a 419-residue protein) is
limited to melanocytes and melanoma cells [39; for review
40]. MITF-Mdel, a variant of MITF-M harboring two in-
frame deletions within the exons 2 and 6, has been identified
as restrictedly expressed in these cells [41]. MITF contains
two TADs responsible for its transcriptional activity; how-
ever, a functional domination of the TAD at N-terminus over
that one at C-terminus has been reported [42]. MITF binds to
DNA as a homodimer or heterodimer with one of the MiT
proteins [29], but does not form heterodimers with other
b-HLH-Zip transcription factors such as MYC, MAX and
USF, despite a common ability to bind to the palindromic
CACGTG E-box motif [43]. It was shown that the heptad
repeat register of the leucine zipper in MITF is broken by a
three-residue insertion that generates a kink in one of the two
zipper helices, which limits the ability of MITF to form
dimers only with those bHLHZip transcription factors that
contain the same type of insertion [43]. Functionally, the
MITF-binding sites in the promoters of target genes involve
E-box: CA[C/T]GTG and M-box, extended E-box with an
additional 50-end flanking thymidine nucleotide:
TCATGTGCT [for review 44].
Genetic alterations in MITF and alternative splicing
Some genetic alterations have been associated with MITF.
Initially, high-density single nucleotide polymorphism
arrays revealed the MITF amplification in up to 20 % of
melanomas, with higher incidence among metastatic mel-
anoma samples [4]. This aberration correlated with
decreased overall patient survival [4]. However, in a recent
study involving targeted-capture deep sequencing, no copy
gains at the MITF locus have been found in a panel of
melanoma metastases [45]. Genetic abnormalities related
to MITF also include single base substitutions in the
regions encoding its functional domains [46]. These
somatic mutations, however, do not affect the DNA-bind-
ing ability of MITF in melanoma cells [47]. Recently, two
independent studies have identified a rare oncogenic
MITFE318K variant representing a gain-of-function allele
for MITF that is present in patients with familial melanoma
and a small fraction of sporadic melanomas [48, 49]. MITF
E318K has been described as a medium-penetrance gene in
melanoma associated with multiple primary melanomas
developed in its carriers [50, 51], and as predisposing to
renal carcinoma as well [48].
Alternative splicing is another mechanism of MITF
regulation in melanoma. Two spliced variants of MITF,
MITF(?) containing an internal six-amino acid fragment
encoded by exon 6a and MITF(-) that lacks this fragment,
have been described. These two variants possess different
activity, with anti-proliferative property of MITF(?). This
effect is tightly related to the interaction between the
N-terminal fragment of MITF(?) with its specific hexa-
peptide [52]. Activation of the MEK1-ERK2 (extracellular
signal-regulated kinase 2) pathway, independently of the
mutational status of BRAF and NRAS, has been indicated as
a mechanism underlying the expression of MITF splice
variants [53]. Additionally, the quantification of these
variants in a panel of 86 melanoma samples revealed the
apparently increased expression of MITF(-) in metastatic
melanomas [53].
Transcriptional activators of MITF
The transcriptional control of MITF is governed by a
number of transcription factors and their regulators asso-
ciated with signaling pathways involved in diverse cellular
processes (Fig. 1). SOX10 (sex-determining region Y-box
10)-responsive element was found between -264 and -
266 in the MITF promoter [54]. In addition, an activating
frameshift or non-sense mutations in SOX10 have been
identified in melanoma cells, and MITF and SOX10 have
been found mutated in a mutually exclusive manner [46].
The nuclear localization of SOX10 is maintained by a
protein tyrosine kinase TYRO3 [55]. SOX10 also cooper-
ates with CREB (cAMP response element-binding protein)
in the responsiveness of MITF to a-MSH (a-melanocyte-
stimulating hormone)-cAMP signaling. This constitutes a
tightly restricted mechanism of regulation due to a ubiq-
uitous expression of CREB and a cell type-limited
expression of SOX10 [56]. CREB is targeted by a number
of regulators that promote its phosphorylation at Ser133,
thus activating CREB-dependent transcription (Fig. 1) [57;
for review 58]. It has been demonstrated that p38, activated
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by either UV (ultraviolet radiation) or receptors, e.g., KIT,
phosphorylates CREB and promotes its binding to the
MITF promoter [57]. p21Cip1, a cell cycle inhibitor, has
been identified as a CREB co-factor involved in cAMP-
dependent MITF expression in melanoma [59]. MITF
expression can be also mediated by the complex of two key
effectors of the Wnt (wingless-type) signaling pathway,
LEF1 (lymphoid enhancer-binding factor 1) and b-catenin
[20, 60]. In contrast to b-catenin, a phenotype-specific
expression of LEF1 has been shown in melanoma cells
limiting LEF1/b-catenin-dependent MITF transcription to a
defined cellular context [20]. Importantly, MITF can
cooperate with LEF1 as a non-DNA-binding coactivator to
enhance its own expression [60]. It has been also demon-
strated that mediators of a-MSH/cAMP/PKA (protein
kinase A) signaling can redirect b-catenin to the CREB-
specific promoters to activate transcription of CREB target
genes including MITF [61]. Most recently, a transcription
factor involved in epithelial–mesenchymal transition [62;
for review 63, 64], ZEB2 (zing finger E-box binding pro-
tein 2) has been shown to activate MITF expression, and a
ZEB2 loss that resulted in a decreased MITF level and
several MITF-dependent target genes was associated with
melanoma progression [65]. In contrast to activating
potential of ZEB2 on the MITF promoter, ZEB1 has been
found to directly repress MITF expression in retinal pig-
ment epithelium [66]. Thus, the role of ZEB1 in the context
of MITF expression in melanoma needs to be elucidated.
On the level of chromatin remodeling, it has been dem-
onstrated that a SWI/SNF complex containing BRM
(Brahma) or BRG1 (Brahma-related gene 1) promotes
MITF expression [67].
Transcriptional repressors of MITF
Several transcription factors have been identified as direct
repressors of MITF (Fig. 1). Inverse expression of GLI2
(glioma-associated oncogene family member 2) and MITF-
M, relating to the mutually exclusive transcriptional pro-
grams, has been observed in melanoma cells [26]. GLI2 is
a Kruppel-like transcription factor activated by TGFb
(transforming growth factor b) [26]. Furthermore, a GLI2
binding site was identified in the -334/-296 region of the
MITF promoter confirming direct inhibitory activity of
GLI2 towards MITF [68]. The contribution of PAX3
(paired box 3) to MITF expression represents another
melanoma-specific mechanism. Although positive regula-
tion of MITF by PAX3 in melanocytes is well described
[69], PAX3 is thought to function independently of MITF
[70] or even play a repressive role on MITF expression in
melanoma [21]. PAX3 is activated by PI3 K (phosphati-
dylinositol 3-kinase) [71] and STAT3 (signal transducer
and activator of transcription 3) [72] in melanoma cells,
and a negative PAX3-dependent regulation of MITF
expression is mediated by BRN2 encoded by POU3F2 [21,
71]. Notably, BRN2-mediated repression of MITF tran-
scription represents a mechanism distinguishing between
melanoma cells and melanocytes due to the lack of BRN2
expression in the latter, which might be explained by the
involvement of melanoma-specific BRAFV600E in BRN2
Fig. 1 Transcriptional and post-transcriptional regulation of MITF
expression. The variety of MITF regulators, activated by diverse
signaling pathways often modified in melanoma, comprises a number
of transcription factors either promoting MITF expression (positive
regulators; shown in green) or inhibiting its transcription (negative
regulators; shown in red). Upstream regulators of these transcription
factors may indirectly affect MITF level. A correlation is also
observed between MITF level and activity of transcription factors,
e.g., NF-jB, not operating on MITF promoter. Moreover, a chroma-
tin-remodeling complex SWI/SNF promotes MITF expression. In
addition, MITF transcript can be either negatively regulated by miRs,
or stabilized by the association with CRD-BP
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upregulation [73]. Moreover, inverse expression of MITF
and BRN2 was shown in vitro [8] and in vivo [7]. The
antagonistic MITF and PAX3 expression has been pro-
posed as a switch model in which MITF and miR-211,
residing in the sixth intron of TRPM1, can activate one
cellular program while suppressing another one driven by
PAX3 and BRN2 [9, 21, 74]. MITF repression is also
mediated by DEC1 (differentially expressed in chondro-
cytes protein 1) whose recruitment to the MITF promoter is
regulated by HIF1 (hypoxia-inducible factor 1) [75].
As HIF1a is a MITF target [76] and can be expressed in
melanoma cells not only under hypoxic conditions [77],
this mechanism constitutes an interesting negative feed-
back loop regulating MITF expression.
Several proteins have been found to indirectly suppress
MITF expression by acting as upstream inhibitors of
positive regulators of MITF expression (Fig. 1). Indepen-
dently of its effect on GLI2, TGFb inhibits PKA that
otherwise promotes CREB-dependent MITF transcription
[68]. DKK1 (Dickkopf-1), a secreted inhibitor of the Wnt/
b-catenin pathway, has been shown to suppress both MITF
expression and the MITF-dependent differentiation pro-
gram [78]. Accordingly, both DKK1 expression and
secretion have been substantially reduced in the multicel-
lular anchorage-independent melanospheres showing high
expression of MITF and numerous MITF target genes [79].
ATF2 (activating transcription factor 2) displays inhibitory
activity towards SOX10 both in melanocytes and mela-
noma cells, resulting in a decreased MITF transcript level
[80]. A co-immunoprecipitation approach confirmed
selective affinity of BCSC1 (breast cancer suppressor
candidate-1) to SOX10, but not other MITF regulators such
as CREB, and down-regulated MITF mRNA level was
observed upon BCSC-1 overexpression [81]. MITF
expression is also affected by IFN-c (interferon c) that
inhibits CREB binding to the MITF promoter by inducing
the association of CBP (CREB binding protein) with
STAT1 [82].
Regulation of MITF transcript stability
Melanoma cells show high expression of CRD-BP (coding
region determinant-binding protein), an mRNA-binding
protein that has been found to stabilize MITF transcript
[83]. MITF transcript is also under control of several small
non-coding RNAs, microRNAs (miRs), which promote
mRNA degradation or suppress protein synthesis via
binding to 30-UTR of a target transcript [23]. miR-137,
located in the locus 1p22, negatively regulates MITF [84,
85]. No mutations have been found in the putative miR-
137-binding sites in the MITF mRNA 30-UTR, however,
miR-137 possesses a 15-bp tandem repeat in the pre-miR-
137 sequence that alters the processing and function of
miR-137 in melanoma cell lines [84]. In metastatic mela-
noma samples, MITF transcript has been determined as a
target of miR-182-mediated degradation [86]. miR-182 is a
member of the miR cluster residing in a chromosomal
locus (7q31–34) frequently amplified in melanomas.
Interestingly, overexpression of MITF has been related to
the suppression of the miR-182-dependent pro-invasive
effect [86]. p53-dependent miR-182 has been also found to
down-regulate MITF in uveal melanoma [87]. The 30-UTR
of MITF transcript is also targeted by miR-148 [88], miR-
101 [89] and miR-218, and inverse correlation between
MITF and miR-218 has been observed in melanocytes and
melanoma cell lines [90]. Notably, exosome-dependent
miR exchange between melanoma cells may influence
MITF transcript level as well [for review 91].
Regulation of MITF protein level and activity
The transcriptional activity of MITF depends on its post-
translational modifications and availability of co-operating
partners (Fig. 2). MITF can be regulated by phosphoryla-
tion maintained by ERK1/2 (at Ser73), p90RSK (at Ser409)
[92], GSK3b (at Ser298) [93, 94] and p38 (at Ser307) [95]. In
general, phosphorylation enhances transcriptional activity
of MITF [94, 95; for review 96]. The phosphorylation at
Ser73 promotes the interaction with a MITF co-factor,
histone acetyl transferase p300/CBP within the transacti-
vation domain of MITF [92]. On the other hand, this
modification promotes the binding of PIAS3 (protein
inhibitor of activated STAT3) that involves the N-terminal
fragment of PIAS3 and the leucine zipper of MITF [97,
98]. Interaction with PIAS3 leads to the attenuation of
MITF transcriptional activity. This effect is, however,
inhibited when MITF is phosphorylated at Ser409 in a
p90RSK-dependent manner [97]. The phosphorylation of
MITF at Ser73, a residue located within a degradation-
promoting PEST sequence, is also a prerequisite to the
MITF proteasome-dependent turnover [99] e.g., in
response to ultraviolet C radiation [100]. Lys201 has been
identified as a site of UBC9-mediated ubiquitylation of
MITF [99]. Proteasome-mediated MITF protein degrada-
tion has also been observed after double phosphorylation at
Ser73 and Ser409 [92]. An unphosphorylatable mutant at
Ser73/Ser409 has been very stable but transcriptionally
incompetent [92], indicating that signals promoting tran-
scriptional activity and degradation of MITF protein are
coupled in melanoma cells. Both phosphorylations pro-
moting MITF degradation depend on melanoma-specific
BRAFV600E causing the enhanced activation of MAPK
(MAP kinase)/ERK1/2 pathway [101]. Deubiquitinase
USP13 (ubiquitin-specific protease 13) has been linked to
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the protection of MITF from proteasomal degradation in
melanoma cells [102]. MITF can be also processed by the
effector caspases. It has been demonstrated in melanoma
cells that MITF-derived C-terminal peptide cleaved by
these proteases has a pro-apoptotic function [103].
MITF activity is also modulated by SUMOylation at two
lysine residues, Lys182 and Lys316 [104]. SUMOylation of
MITF depends on an E1 SUMO-activating heterodimeric
enzyme SAEI/SAEII and E2 SUMO-conjugating enzyme
UBC9 [104] (Fig. 2). It has been concluded that this
modification plays an essential role in the regulation of
MITF activity, and non-SUMOylatable MITF mutants
displayed increased transcriptional activity on distinct sets
of target genes [48, 49, 104, 105]. It has been also indicated
that PIAS3 can promote MITF SUMOylation at both SU-
MOylation sites [105]; however, this observation has not
been clearly supported by another report [104]. A recent
study on melanoma patients bearing the MITFE318K variant
[51], in which a point mutation occurs at the consensus
binding site for SUMOylation [105], supports the conclu-
sion that this substitution does not affect MITF protein
stability and nuclear localization.
Besides aforementioned regulations, MITF activity also
depends on the availability of co-operating partners such as
p300/CBP [92]. p300/CBP is a versatile regulator that links
transcription factors bound to DNA with a basal
transcriptional machinery, thus promoting the assembly of
pre-initiation complex [for review 106]. Immunofluores-
cence and immunoprecipitation studies have demonstrated
that MITF can physically interact with BRM and BRG1,
and depending on the type of SWI/SNF complex composed
of either the BRG1 or BRM subunit, different sets of
MITF-dependent genes are activated [107]. This, however,
is not an exclusive role of the BRG1-containing SWI/SNF
complex in melanoma since its MITF-independent activity
has been shown as well [108]. SOX10 can synergistically
activate the MITF-dependent genes as demonstrated for
MET [109]. It has been also shown that MITF can redirect
b-catenin from the Wnt signaling pathway, and engage it to
the activation of MITF-dependent genes [110]. Thus, SWI/
SNF complex, SOX10 and b-catenin can function not only
as activators of MITF expression (Fig. 1), but also as its
co-factors. HINT1 (histidine triad nucleotide-binding pro-
tein 1) has been identified as an inhibitor of transcriptional
activity of MITF acting through binding the chromatin at
the MITF sites [111]. Moreover, since HINT1 expression is
lost in primary melanomas [111], it may support a role of
MITF in melanomagenesis.
The mechanisms behind the regulation of MITF level
and activity are still being explored. Most recently, very
interesting correlations have been observed between
activity of MITF and other transcription factors, probably
Fig. 2 A schematic domain structure of MITF-M protein, a
melanocyte/melanoma-specific isoform, and its key regulatory mech-
anisms. MITF-M comprises 419 amino acids. The functional domains
of MITF-M common for all isoforms are encoded by the exons from 2
to 9. Phosphorylation enhances the transcriptional activity of MITF.
However, this modification may also promote proteasome-dependent
degradation of MITF, or enhance interaction between MITF and
p300/CBP. MITF can be subjected to USP13-mediated deubiquity-
lation, thus preventing MITF from proteasomal degradation. In
addition, MITF can be a target for other modifications, including
SUMOylation and caspase-mediated cleavage
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not operating on the MITF promoter (Fig. 1). HOXA1
(homeobox transcription factor 1) has been identified as a
potent inhibitor of MITF expression whose activity might
be concomitant with the activation of the TGFb pathway
[112]. An interesting repression mechanism has been
reported in melanoma cells expressing IL-1R (interleukin-1
receptor). The stimulation of melanoma cells with inter-
leukin-1a or 1b resulted in the reduction of MITF
expression, and it has been suggested that this process is
NF-jB-dependent [113]. Accordingly, a suppressive role
of the NF-jB signaling on MITF level has been reported
[114]. A reverse correlation has been observed between
MYC-related chromosomal copy number gains in 8q24 and
MITF expression [115]. In contrast, suppression of ETV1
(E twenty-six variant 1) was associated with a decreased
level of MITF protein [116]. Whether c-MYC and ETV1
can act as direct regulators of MITF remains to be eluci-
dated. Other poorly characterized regulators have been
associated with MITF level, and the detailed mechanisms
of their actions need to be clarified. PRMT5 (protein
arginine methyltransferase 5) is an enzyme involved in
post-translational protein modifications. PRMT5 expres-
sion has been found to be increased in melanoma, and
siRNA-mediated depletion of PRMT5 resulted in a sub-
stantial decrease in the level of MITF protein indicating a
positive regulatory effect [117]. A similar influence on the
MITF level has been demonstrated for PDE4D (phospho-
diesterase subtype 4D), and PDE4D-depleted cells have
shown a decreased MITF transcript level [118].
Final conclusions
MITF operates within a wide range of activity levels
determining melanoma cell fate (Fig. 3) [20, 24–27; for
review 22, 23, 28]. Melanoma cells expressing MITF at
high level can either differentiate or proliferate. Low
activity of MITF is related to stem cell-like or invasive
potential. Finally, long-term MITF suppression drives cell
senescence. Although genetic alterations, including muta-
tions and amplification of MITF, are found in melanoma
samples [4, 46, 48, 49], fluctuating MITF activity in mel-
anoma cells is rather due to microenvironmental cues,
critical epigenetic states and modifications of upstream
signaling pathways [7, 8, 10, 79, 104–138]. Different
combinations of those factors determine transcriptional
activity of MITF which in turn contributes to diverse cel-
lular capabilities. This may explain a variable MITF
expression across melanoma specimens but also between
different areas of individual tumor samples reflecting both
inter-tumoral heterogeneity and diversity of melanoma cell
subpopulations comprising a tumor mass [123, 124; for
review 125].
MITF does not exhibit a druggable target, and MITF-
aimed approaches are thought to be rather based on the
modulation of its upstream regulatory pathways [126, 127].
A number of natural and synthetic compounds have been
used to modify MITF activity. A few natural compounds
that either reduced or increased MITF transcript level in
heterogeneous patient-derived melanoma populations were
identified in our laboratory [128]. A dietary flavonoid
fisetin that targets Wnt/b-catenin pathway has substantially
reduced MITF expression and influenced MITF-dependent
cellular processes [129]. Downregulation of MITF at the
transcriptional level was observed for ciglitazone that also
showed anti-melanoma effects in vivo [130]. Hirsein A
reduced the expression of MITF by modulating the
expression of diverse components of MAPK signaling
pathway [131]. Several studies have linked a high MITF
level with the resistance to MAPK-pathway inhibitors
[132, 133; for review 134–136]. MITF targets are up-reg-
ulated by MAPK-pathway inhibitors [137], and enforced
expression of MITF in BRAFV600E melanoma cells pro-
motes resistance towards inhibitors of RAF, MEK and
ERK [for review 134]. As MITF expression can be reduced
by histone deacetylase inhibitors (HDACi) [138], com-
bined HDAC and MAPK inhibition was shown to prevent
MITF-driven resistance in melanoma cells [132]. Another
study suggests, however, that intrinsically resistant mela-
nomas can be characterized by low expression/activity of
MITF accompanied by enhanced activity of NF-jB sig-
naling, and BRAF inhibition in MITF-high, drug-sensitive
cells induces a transition to the MITF-low/NF-jB–high
state [114]. Most recent findings that modulation of MITF
Fig. 3 MITF expression and activity in melanoma cells are deter-
mined by genetic alterations, epigenetics, changes in upstream
signaling pathways and microenvironment. Different combinations
of those factors result in varied transcriptional activity of MITF which
contributes to diverse cellular programs from differentiation and
proliferation at high level of MITF activity to stemness and
senescence at the lowest one. However, the outcome is not stable
and can be modified by fluctuations in microenvironment-dependent
critical epigenetic states and signaling pathways. Several MITF-
dependent feedback mechanisms are also determined
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activity can drive phenotype switching in vivo, and abro-
gating MITF activity in melanoma leads to tumor
regression, but a low level of wild-type MITF is oncogenic
[27] indicate that further studies are needed.
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